RH
XMUN:RS1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
RH
XMUN:RS1
|
US |
|
Innate Pharma SA
F:IDD
|
FR |
Wall St Price Targets
RS1 Price Targets Summary
RH
According to Wall Street analysts, the average 1-year price target for RS1 is 137.6 EUR with a low forecast of 74.05 EUR and a high forecast of 214.83 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RS1's stock price target?
Price Target
137.6
EUR
According to Wall Street analysts, the average 1-year price target for RS1 is 137.6 EUR with a low forecast of 74.05 EUR and a high forecast of 214.83 EUR.
What is the Revenue forecast for RH?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 8 years is 9%.
What is the Gross Profit forecast for RH?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 10%. The projected CAGR for the next 8 years is 9%.
What is the Operating Income forecast for RH?
Projected CAGR
14%
The compound annual growth rate for Operating Income over the next 8 years is 14%.
What is the Pre-Tax Income forecast for RH?
Projected CAGR
25%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 25%.
What is the Net Income forecast for RH?
Projected CAGR
26%
The compound annual growth rate for Net Income over the next 8 years is 26%.
